Form 4: Inhibikase Therapeutics Director Roberto Bellini Granted Over 108,000 Stock Options

Inhibikase Therapeutics, Inc. Director Roberto Bellini was granted 108,176 stock options with an exercise price of $1.95, vesting on June 30, 2026, or earlier.

Summary

• Roberto Bellini, a Director of Inhibikase Therapeutics, Inc. (IKT), acquired 108,176 stock options on June 30, 2025.
• The stock options have an exercise price of $1.95 per share.
• These options will vest on the earlier of June 30, 2026, or the day prior to the next annual meeting of stockholders, subject to Mr. Bellini's continued service through such date.
• The expiration date for these stock options is June 30, 2032.
• Following this transaction, Roberto Bellini directly beneficially owns 108,176 derivative securities.
• Mr. Bellini has granted a Limited Power of Attorney to David McIntyre and Mark Iwicki, effective July 2, 2025, to prepare and file SEC reports on his behalf.

Sentiment

Score: 7

Explanation: The grant of stock options to a director is generally a positive signal as it aligns interests and incentivizes long-term performance. It's a routine compensation event, not indicative of major strategic shifts, hence a moderate positive score.

Positives

• The grant of stock options to a director aligns their interests with shareholders, incentivizing long-term performance and value creation.
• The vesting schedule encourages continued service and commitment from the director, promoting stability in governance.

Risks

• The value of the stock options is contingent on Inhibikase Therapeutics' common stock price exceeding the exercise price of $1.95; if the stock price remains below this threshold, the options may expire worthless.
• Vesting of the options is subject to the director's continued service, meaning the options could be forfeited if service ceases before the vesting conditions are met.

Future Outlook

The grant of stock options with a future vesting date indicates an expectation of continued service from the director and aligns their long-term incentives with the company's performance and potential future growth.

Management Comments

• The options will vest on the earlier of June 30, 2026 or the day prior to the next annual meeting of stockholders, subject to the director's continued service through such date.

Industry Context

This is a standard compensation practice in the biotechnology and pharmaceutical industry, where equity grants are commonly used to attract, retain, and incentivize key personnel, including directors, by aligning their financial interests with the long-term success of the company and its stock performance.

Comparison to Industry Standards

• Granting stock options to directors is a common practice across publicly traded companies, particularly in growth-oriented sectors like biotech, to align director incentives with shareholder value creation.
• The exercise price of $1.95, which is typically the market price at the time of grant for compensatory options, is standard for such grants.
• A vesting period of approximately one year (until June 30, 2026) for director options is within typical industry ranges, balancing immediate incentive with retention.

Corporate Governance

Stakeholder Impact

• Shareholders: The grant of stock options aligns the director's financial interests with shareholder value creation, potentially leading to better long-term performance and strategic decisions.
• Management: The Power of Attorney granted by the director streamlines compliance with SEC reporting requirements for insider transactions, benefiting the company's legal and finance teams.

Next Steps

• Roberto Bellini is expected to continue his service as a Director of Inhibikase Therapeutics, Inc.
• The granted stock options will vest on the earlier of June 30, 2026, or the day prior to the next annual meeting of stockholders.

Key Dates

Keywords

Inhibikase Therapeutics, IKT, Stock Options, Director Compensation, SEC Form 4, Insider Transaction, Equity Grant, Roberto Bellini, Corporate Governance